Weiss Ratings Reaffirms Sell (E+) Rating for OrthoPediatrics (NASDAQ:KIDS)

Key Points

• Weiss Ratings has reaffirmed a "sell (e+)" rating for OrthoPediatrics (NASDAQ: KIDS), indicating ongoing concerns about the company's stock performance.
• Despite the sell rating, other analysts like Wall Street Zen and BTIG Research have issued conflicting ratings, with Wall Street Zen raising its rating to "hold" and BTIG setting a "buy" rating with a lowered target price of $39.00.
• OrthoPediatrics reported earnings per share of ($0.11), surpassing expectations, but registered a negative return on equity of 6.36% and a significant net margin of 18.92%.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report)'s stock had its "sell (e+)" rating restated by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

KIDS has been the subject of several other reports. Wall Street Zen raised OrthoPediatrics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. BTIG Research dropped their target price on OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. JMP Securities set a $35.00 target price on OrthoPediatrics and gave the stock a "market outperform" rating in a research report on Friday, August 8th. Finally, Citigroup restated a "market outperform" rating on shares of OrthoPediatrics in a research report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OrthoPediatrics has an average rating of "Moderate Buy" and a consensus price target of $34.14.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS opened at $18.10 on Wednesday. The stock has a fifty day simple moving average of $19.63 and a two-hundred day simple moving average of $21.15. OrthoPediatrics has a 1-year low of $16.59 and a 1-year high of $32.00. The firm has a market cap of $453.77 million, a price-to-earnings ratio of -10.11 and a beta of 1.02. The company has a current ratio of 6.66, a quick ratio of 3.43 and a debt-to-equity ratio of 0.27.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.06. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%.The business had revenue of $61.08 million during the quarter, compared to analyst estimates of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. Analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current year.

Insider Activity

In other OrthoPediatrics news, CFO Fred Hite acquired 5,076 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were bought at an average price of $19.41 per share, for a total transaction of $98,525.16. Following the completion of the transaction, the chief financial officer owned 213,065 shares of the company's stock, valued at approximately $4,135,591.65. This represents a 2.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 32.70% of the company's stock.

Institutional Investors Weigh In On OrthoPediatrics

A number of large investors have recently added to or reduced their stakes in KIDS. Millennium Management LLC raised its position in OrthoPediatrics by 55.3% during the first quarter. Millennium Management LLC now owns 656,578 shares of the company's stock valued at $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in OrthoPediatrics by 116.5% during the second quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company's stock valued at $7,173,000 after purchasing an additional 179,733 shares in the last quarter. Paradigm Capital Management Inc. NY raised its position in OrthoPediatrics by 1,607.0% during the first quarter. Paradigm Capital Management Inc. NY now owns 170,700 shares of the company's stock valued at $4,204,000 after purchasing an additional 160,700 shares in the last quarter. Goldman Sachs Group Inc. raised its position in OrthoPediatrics by 112.3% during the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock valued at $4,937,000 after purchasing an additional 106,041 shares in the last quarter. Finally, Brown Advisory Inc. raised its position in OrthoPediatrics by 6.2% during the first quarter. Brown Advisory Inc. now owns 1,628,747 shares of the company's stock valued at $40,116,000 after purchasing an additional 94,719 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company's stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.